Intro; Contents; Chapter 1: Overview: The Pathobiology of Head and Neck Cancer; References; Chapter 2: Targeting the ErbB Family in Head and Neck Cancer; 2.1 Introduction; 2.2 Regulation of EGFR and the ErbB Family in Normal Cells; 2.2.1 Ligand Binding and Dimerization: Activation of ErbB Proteins in Normal Cells; 2.2.2 ErbB Trafficking and Other Mechanisms to Limit EGFR Function in Normal Cells; 2.3 Causes and Consequences of Altered EGFR/ErbB Function in SCCHN; 2.3.1 Overexpression of EGFR and Its Ligands
2.4.3 Targeting Critical EGFR/ErbB Effectors2.4.4 EGFR/ErbB2 and Immunotherapy/Immune Response; 2.5 Mechanisms of Resistance to Anti-EGFR Therapies; 2.5.1 EGFR-Intrinsic Resistance; 2.5.2 Elevated Expression of ErbB Family Members; 2.5.3 VEGF Expression; 2.5.4 STAT3 Expression; 2.5.5 KRAS and PI3K Mutation; 2.5.6 Microenvironment; 2.5.7 Epigenetic Changes; 2.5.8 Other Factors; 2.6 Toxicity and Tolerance; 2.7 Conclusions and New Frontiers in Drug Discovery; References; Chapter 3: c-MET in Head and Neck Squamous Cell Carcinoma; 3.1 Introduction; 3.2 c-MET Structure and Normal Function
3.2.1 c-MET General Structure3.2.2 c-MET Ligand: HGF/SF; 3.2.3 c-MET Trafficking; 3.2.4 c-MET-Associated Signaling; 3.3 c-MET Critical Interactions and Functions; 3.3.1 c-MET and the Epidermal Growth Factor (EGF) Family of Receptors; 3.3.2 c-MET and SRC; 3.3.3 c-MET in Epithelial-to-Mesenchymal Transition (EMT); 3.4 Dysregulation of HGF/c-MET in HNSCC; 3.4.1 c-MET Overexpression and Amplification; 3.4.2 c-MET Mutation; 3.4.3 Microenvironment and HGF/SF; 3.5 Clinical Applications of HGF/c-MET-Targeted Therapy; 3.5.1 Foretinib; 3.5.2 Tivantinib; 3.5.3 Additional Small-Molecule Inhibitors
0
8
8
This book will benefit researchers interested in better understanding the biology of squamous cell cancers of the head and neck (SCCHN), with the goals of designing therapies, identifying risk factors and investigating the molecular basis of the disease.